Comprehensive Metabolomic Characterization of Coronary Artery Diseases.

BACKGROUND Pathogenesis and diagnostic biomarkers for diseases can be discovered by metabolomic profiling of human fluids. If the various types of coronary artery disease (CAD) can be accurately characterized by metabolomics, effective treatment may be targeted without using unnecessary therapies and resources. OBJECTIVES The authors studied disturbed metabolic pathways to assess the diagnostic value of metabolomics-based biomarkers in different types of CAD. METHODS A cohort of 2,324 patients from 4 independent centers was studied. Patients underwent coronary angiography for suspected CAD. Groups were divided as follows: normal coronary artery (NCA), nonobstructive coronary atherosclerosis (NOCA), stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI). Plasma metabolomic profiles were determined by liquid chromatography-quadrupole time-of-flight mass spectrometry and were analyzed by multivariate statistics. RESULTS We made 12 cross-comparisons to and within CAD to characterize metabolic disturbances. We focused on comparisons of NOCA versus NCA, SA versus NOCA, UA versus SA, and AMI versus UA. Other comparisons were made, including SA versus NCA, UA versus NCA, AMI versus NCA, UA versus NOCA, AMI versus NOCA, AMI versus SA, significant CAD (SA/UA/AMI) versus nonsignificant CAD (NCA/NOCA), and acute coronary syndrome (UA/AMI) versus SA. A total of 89 differential metabolites were identified. The altered metabolic pathways included reduced phospholipid catabolism, increased amino acid metabolism, increased short-chain acylcarnitines, decrease in tricarboxylic acid cycle, and less biosynthesis of primary bile acid. For differential diagnosis, 12 panels of specific metabolomics-based biomarkers provided areas under the curve of 0.938 to 0.996 in the discovery phase (n = 1,086), predictive values of 89.2% to 96.0% in the test phase (n = 933), and 85.3% to 96.4% in the 3-center external sets (n = 305). CONCLUSIONS Plasma metabolomics are powerful for characterizing metabolic disturbances. Differences in small-molecule metabolites may reflect underlying CAD and serve as biomarkers for CAD progression.

[1]  H. Ho,et al.  Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. , 2015, Journal of the American College of Cardiology.

[2]  D. Munn,et al.  Prevention of T cell–driven complement activation and inflammation by tryptophan catabolism during pregnancy , 2001, Nature Immunology.

[3]  A. Lisowska,et al.  Decreased free sphingoid base concentration in the plasma of patients with chronic systolic heart failure. , 2012, Advances in medical sciences.

[4]  G. Schuler,et al.  Effect of Exercise on Coronary Endothelial Function in Patients With Coronary Artery Disease , 2000 .

[5]  Jianhui Zhu,et al.  Infection and atherosclerosis: emerging mechanistic paradigms. , 1999, Circulation.

[6]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[7]  Anders Larsson,et al.  Large-scale Metabolomic Profiling Identifies Novel Biomarkers for Incident Coronary Heart Disease , 2014, PLoS genetics.

[8]  Frederick P Roth,et al.  Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia , 2005, Circulation.

[9]  Zeneng Wang,et al.  Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk , 2013 .

[10]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[11]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[12]  A. Xu,et al.  Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice , 2015, Circulation.

[13]  M. Miyazaki,et al.  Saturated phosphatidic acids mediate saturated fatty acid-induced vascular calcification and lipotoxicity. , 2015, The Journal of clinical investigation.

[14]  Dudley J Pennell,et al.  Low diagnostic yield of elective coronary angiography. , 2010, The New England journal of medicine.

[15]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[16]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[17]  Xin Lu,et al.  Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. , 2013, Cancer research.

[18]  P. Libby,et al.  Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.

[19]  Werner Moshage,et al.  Detection of Coronary Artery Stenoses by Contrast-Enhanced, Retrospectively Electrocardiographically-Gated, Multislice Spiral Computed Tomography , 2001, Circulation.

[20]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[21]  Hironari Akasaka,et al.  IDENTIFICATION OF THE TWO-PHASE MECHANISM OF ENDOGENOUS OMEGA-6 FATTY ACID, ARACHIDONIC ACID, REGULATING VASCULAR INFLAMMATION BY TARGETING CYCLOOXYGENASE-2 AND MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 , 2016 .

[22]  Katherine C. Wu,et al.  Metabolic Rates of ATP Transfer Through Creatine Kinase (CK Flux) Predict Clinical Heart Failure Events and Death , 2013, Science Translational Medicine.

[23]  W. Kraus,et al.  Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. , 2012, American heart journal.

[24]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[25]  R. Schneiter,et al.  Lipid signalling in disease , 2008, Nature Reviews Molecular Cell Biology.

[26]  Chiadi E. Ndumele,et al.  The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. , 2015, Journal of hepatology.

[27]  F. Bäckhed,et al.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.

[28]  W. Daniel,et al.  Noninvasive coronary angiography--an acceptable alternative? , 2001, The New England journal of medicine.

[29]  E. Ntzani,et al.  Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. , 2012, JAMA.

[30]  Raimund Pechlaner,et al.  Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014 .

[31]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[32]  Christian Baumgartner,et al.  Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. , 2008, The Journal of clinical investigation.

[33]  I. Wilson,et al.  Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. , 2007, Journal of proteome research.